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Abstract: Lamellarins are a large family of marine alkaloids with potential anticancer activity that have 
been isolated from diverse marine organisms, mainly ascidians and sponges. All lamellarins feature a 3,4-
diarylpyrrole system. Pentacyclic lamellarins, whose polyheterocyclic system has a pyrrole core, are the 
most active compounds. Some of these alkaloids are potently cytotoxic to various tumor cell lines. To date, 
Lam-D and Lam-H have been identified as lead compounds for the inhibition of topoisomerase I and HIV-1 
integrase, respectively—nuclear enzymes which are over-expressed in deregulation disorders. Moreover, 
these compounds have been reported for their efficacy in treatment of multi-drug resistant (MDR) tumors 
cells without mediated drug efflux, as well as their immunomodulatory activity and selectivity towards 
melanoma cell lines. This article is an overview of recent literature on lamellarins, encompassing their 
isolation, recent synthetic strategies for their total synthesis, the preparation of their analogs, studies on 
their mechanisms of action, and their structure-activity relationships (SAR). 
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Introduction: 
Lamellarins are a large family of marine alkaloids characterized by their unusual structures and important 
activities. From a structural perspective, two groups of lamellarins can be found. Members of the larger of 
the two groups possess a pentacyclic system of 6-oxobenzo[b]pyrano[3,4-b]pyrrolo[2,1-a] with a 
substituted phenyl ring at position 14. Pentacyclic lamellarins may be saturated (Table 1) or unsaturated 
(Table 2)   between positions 8 and 9.  
 
Table 1. Structure of reduced pentacyclic lamellarins 
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Lamellarins R1 R2 R3 R4 R5 R6 R7 R8 R9 Ref 
Lam-A OMe OH OH OMe OMe OMe OMe OH H [1]  
Lam-C OMe OH H OMe OMe OMe OMe OH H [1]  
Lam-C sulf. OMe OSO3Na H OMe OMe OMe OMe OH H [2]  
Lam-E OMe OH H OH OMe OMe OH OMe H [3]  
Lam-F OMe OH H OH OMe OMe OMe OMe H [3]  
Lam-G OH OMe H H OH OMe OH OMe H [3]  
Lam-G sulf. OH OMe H OSO3Na OH OMe OH OMe H [2]  
Lam-I OMe OH H OMe OMe OMe OMe OMe H [4]  
Lam-J OMe OH H H OH OMe OMe OMe H [4]  
Lam-K OMe OH H OH OMe OMe OMe OH H [4]  
Lam-L OMe OH H H OH OMe OH OMe H [4]  
L sulf. OMe OSO3Na H H OH OMe OH OMe H [2]  
Lam-S OH OH H H OH OMe OH OH H [2]  
Lam-T OMe OH H OMe OMe OMe OH OMe H [5]  
Lam-T sulf. OMe OSO3Na H OMe OMe OMe OMe OH H [5]  
Lam-U OMe OH H H OMe OMe OH OMe H [2]  
Lam-U sulf. OMe OSO3Na H H OMe OMe OH OMe H [5]  
Lam-V OMe OH OH OMe OMe OMe OH OMe H [5]  
Lam-V sulf. OMe OSO3Na OH OMe OMe OMe OH OMe H [5]  
Lam-Y OMe OH H H OMe OH OH OMe H [2]  
Lam-Y sulf. OMe OSO3Na H H OMe OH OH OMe H [5]  
Lam-Z OH OMe H H OH OMe OH OH H [2]  
Lam-β OMe OH H H OH OH OH OMe H [6]  
 3 
Lam-γ OMe OH H OH OMe OMe OH OMe OMe [7]  
Lam-χ triacetate OMe OAc H H OAc OMe OMe OAc H [8]  
Dihydro- Lam- η OMe OH H H OMe OMe OMe OMe H [8]  
 
 
Table 2. Structure of oxidized pentacyclic lamellarins 
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Lamellarins R1 R2 R3 R4 R5 R6 R7 Ref 
Lam-B OMe OH OMe OMe OMe OMe OH [1]  
Lam-B sulf. OMe OSO3Na OMe OMe OMe OMe OH [2]  
Lam-D OMe OH H OH OMe OMe OH [1]  
Lam-H OH OH H OH OH OH OH [3] 
Lam-M OMe OH OH OMe OMe OMe OH [4]  
Lam-N OMe OH H OH OMe OH OMe [4]  
Lam-W OMe OH OMe OMe OMe OH OMe [5]  
Lam-X OMe OH OH OMe OMe OH OMe [2]  
Lam-α OMe OH H OMe OMe OH OMe [7] 
Lam-α sulf. OMe OSO3Na H OMe OMe OH OMe [9]  
Lam-ζ OMe OH OMe OMe OMe OMe OMe [8]  
Lam- Є OMe OH OH OMe OMe OMe OMe [7]  
Lam-η OMe OH H OMe OMe OMe OMe [8]  
Lam-φ OMe OAc OMe OMe OAc OMe OAc [8]  
 
Table 2. Structure of oxidized pentacyclic lamellarins 
 
 
The second group of lamellarins, which are less structurally complex, are derivatives of methyl 3,4-bis(p-
hydroxyphenyl)pyrrole-2-carboxylate, and which differ in their N-pyrrole substituent (Figure 1). 
Lamellarins O (Lam-O) and P (Lam-P) [10] contain a common p-methoxyacetophenone on their N-pyrrole, 
Lam-Q [11] has a un-substituted pyrrole, and Lam-R has an N-(p-hydroxyphenyl)pyrrole [11].  The 
bioactivities of these compounds are not significant. 
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Fig. (1). Structures of lamellarins O–R, lukianol A, ningalins B and D, polycitone A, and purpurone 
 
Lamellarins can be biosynthesized from three molecules of tyrosine or DOPA [4, 11], similarly to several 
related marine alkaloid families such as lukianols [12], ningalins [13], polycitones [14] and purpurone [15] 
(Figure 1). 
Several reviews on lamellarins have recently been published [16]. Herein is covered work related to their 
isolation, synthesis and activity that was published between 2004 and December 2007. 
  
Isolation of lamellarins 
Lamellarins were initially isolated from a prosobranch mollusk of the genus Lamellaria [1] and 
subsequently found in various organisms, mostly ascidians, which are prey of the former. More than thirty 
lamellarins have been isolated to date, but only few show interesting bioactive properties [1-9]. 
Venkateswarlu et al. [7] recently isolated from the Indian red colonial ascidian Didemnum obscurum three 
new lamellarin alkaloids (Lam-γ, Lam-α, and Lam- Є) plus eight known lamellarin alkaloids (Lam-M, 
Lam-K, Lam-K diacetate, Lam-K triacetate, Lam-U, Lam-I, Lam-C diacetate, and Lam-X triacetate). The 
same authors also described from the same ascidian four new lamellarin alkaloids (Lam-ζ, Lam-η, Lam-φ 
and Lam-χ) and seven known lamellarins (Lam-K, Lam-I, Lam-J, Lam-K triacetate, Lam-L triacetate, Lam-
F and Lam-T diacetate) [8]. The structures of the lamellarins isolated by Venkateswarlu et al. [7, 8] were 
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established using standard spectroscopic techniques, and the structure of Lam-K triacetate was confirmed 
by X-ray crystallographic analysis.  
 
Synthesis 
Lamellarins are rather complex structural targets. Several approaches to their synthesis can be found in the 
literature. These fall into two main synthetic categories: (a) pyrrole formation as the cornerstone of the 
synthesis; and (b) transformation of a pre-existing pyrrole derivative through cross-coupling reactions.  
 
a) Pyrrole ring formation  
 
A highly efficient synthesis of Lam-K and Lam-L was described by Ruchirawat et al. [17]. The pyrrole ring 
was constructed via Michael addition followed by a ring-closing reaction of benzyldihydroisoquinoline 
derivatives with ethoxycarbonyl-β-nitrostyrenes (Figure 2). Formation of the pyrrole ring produces the 
dihydropyrrolo[2,1-a]isoquinoline in which all the phenol groups were protected as benzyl-ethers. 
Deprotection by hydrogenolysis followed by base-mediated lactonization gave the natural products. The 
same methodology was used to prepare several natural saturated and unsaturated lamellarins, as well as 
various analogs [18]. 
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Fig. (2) . Synthesis of lamellarins K and L 
 
The same authors reported an elegant preparation of the lamellarin skeleton using a slightly different 
pyrrole ring formation from benzyldihydroisoquinoline and a phenacyl bromide [19]. They used polymer-
supported reagents to simplify the work-up and obviate column chromatography. The pyrrole ring was 
constructed in one pot by quaternization of the isoquinoline followed by an aldol-type condensation. 
Subsequent intramolecular Friedel-Crafts transacylation, and finally, lactonization, afforded the lamellarin 
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skeleton. As shown in Figure 3, polymer-supported reagents were used for the following steps: selective 
monobromination of ortho-substituted acetophenones (Amberlyst A-26 Br3 -form and PVPHP); base-
mediated pyrrole formation via condensation of benzyldihydroisoquinoline with either phenacyl bromide or 
α-nitrocinnamate (Amberlyst A-26 NaCO3 form); and a novel acid-mediated lactone formation via either 
Friedel-Crafts transacylation and lactonization, or O-debenzylation and lactonization (Amberlyst-15). 
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Fig. (3). Synthesis of the lamellarin skeleton with polymer-supported reagents 
 
Several lamellarins and derivatives were obtained by solid-phase synthesis (SPS) on an appropriate solid 
support and under different cleavage conditions [20]. The lamellarin skeleton was synthesized on solid 
phase through formation of the pentacyclic system from an open chain dihydroisoquinolinium salt by an 
intramolecular [3+2] cycloaddition [21]. The use of different Lewis acids as cleavage-deprotection reagents 
in SPS has been exploited for introducing diversity to produce analogs for screening (Figure 4). 
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Fig. (4). Lewis acids for cleavage-deprotection in solid-phase synthesis  
 
A biomimetic synthesis of lamellarin and lukianol skeleton was developed by Steglich et al. [22]. It is 
based on formation of 3,4-diarylpyrrole-2,5-dicarboxylic acid from aryl pyruvic acids and 2-
arylethylamines. The method has been used for the synthesis of ningalin B, Lam-G, Lam-K, lukianol A and 
a lukianol-lamellarin hybrid (Figure5). 
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Fig. (5). Synthesis of lamellarins G and K 
 
Lam-Q dimethyl ether was obtained by Raney Ni reduction of 3,4-diarylpyrrole-2-carboxylates (1) [23], 
which were obtained by cyclization of α-oxoketene-N,S-acetals in the presence of Vilsmeier reagent. Lam-
Q dimethyl ether has been demonstrated to be a synthetic precursor of Lam-O dimethyl ether and lukianol 
A [24].   
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Fig. (6). Synthesis of lamellarin Q dimethyl ether 
 
The total synthesis of Lam-α 20-sulfate [25] has been performed using a Hinsberg-type pyrrole synthesis 
and Suzuki-Miyaura cross-coupling as the key reactions. The synthesis featured an interesting combination 
of protecting groups for the phenols [26]. The pentacyclic system of lamellarins was obtained with two 
orthogonal protecting groups, isopropoxy (13-OiPr) and benzyloxy (20-OBn). The 20-sulfate analog was 
prepared by a sequence comprising debenzylation of Lam-α 20-OBn, formation of the 2,2,2-
trichloroethylsulfate of the resulting 20-OH, deprotection of Lam-α 13-OiPr, and finally, reductive 
elimination of the 2,2,2-trichloroethyl sulfate protecting group (Figure 7). 
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Fig. (7). Synthesis of lamellarin α 20-sulfate 
 
A similar procedure employing the appropiate boronic acids for the cross-coupling reaction has been used 
for the total synthesis of Lam-D, Lam-L, and Lam-N [27]. 
 
The 1,2-diaryl-substituted pyrrolo[2,1-a]isoquinoline skeleton of lamellarins has been obtained by a new 
route via 1,5-dipolar electrocyclization of azomethine ylides (Figure 8) [28]. The reagents comprised the 
stilbenic amides 2 available from the acids obtained by condensation of substituted benzaldehydes with 
phenylacetic acid. Cyclization of the amide 2 using the Bischler-Napieralski procedure afforded 3,4-
dihydroisoquinolines 3. Subsequent reaction of the isoquinolines with ethyl bromoacetate gave the 
quaternary salts, which upon treatment with triethylamine in dry ethanol afforded the pyrrole derivatives. 
Removal of the allylic protecting group with Pd-C and TsOH resulted in simultaneous formation of the 
pentacyclic lamellarin skeleton and lactonization. This elegant method was not used for the preparation of a 
natural product; it was only applied to the construction of the lamellarin skeleton. 
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Fig. (8). Synthesis of the lamellarin skeleton by electrocyclization of azomethine ylides 
 
A recently developed method for rapid access to the pyrroloisoquinoline core structures related to 
lamellarins is based on silver-catalyzed domino cycloisomerization-dipolar cycloaddition of alkynyl N-
benzylideneglycinate 4 and acetylene mono- or di-carboxylate (Figure 9). Reactions conducted at 60ºC in 
toluene using 2,6-di-ter-butyl-4-methylpyridine (DTBMP) as base, and in the absence of oxidants, afforded 
optimal results (Figure 9). Several diversely substituted pyrroloisoquinolines were thus prepared [29]. 
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Fig. (9). Synthesis of pyrroloisoquinoline core structures of lamellarins 
 
b) Transformation of a pyrrole derivative through cross-coupling reactions  
 
Lam-Q and Lam-O have been synthesized on Merrifield resin with N-protected 3,4-dibromopyrrole-2-
carboxylate as scaffold (Figure 10) [30]. The process comprises incorporation of a substituted pyrrole ring 
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onto a p-alkoxy iodo phenyl resin through a Negishi cross-coupling reaction, followed by Suzuki cross-
coupling to introduce the second substituted phenyl ring, and finally, N-alkylation. A Lewis acid was used 
for the final cleavage. The beauty of this strategy is that diversity can be introduced at each step, including 
the final cleavage (by using the appropriate Lewis acid). 
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Fig. (10). Solid phase synthesis of lamellarins O and Q 
 
Lam-G trimethyl ether has been obtained by three successive halogenation/cross couplings of a pyrrole-2-
carboxylate (Figure 11) [31]. Coupling of N-protected bromopyrrole 5 with boronic acid 6 gave the aryl 
pyrrole 7. Treatment of 7 with an equimolar amount of NBS led to selective halogenation at position C5. 
The second coupling with boronic acid 8 under Suzuki conditions gave the diarylpyrrole 9, which, owing to 
the quality of the hydroxyl function as a leaving group, readily underwent cyclization under basic 
conditions.  
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Fig. (11). Synthesis of lamellarin G trimethyl ether 
 
A total synthesis of Lam-D has been developed starting from two sequential and regioselective bromination 
and cross-coupling reactions of the scaffold 10 [32], followed by oxidation, deprotection of the phenol-
groups and lactonization (Figure 12) [33]. 
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Fig. (12). Synthesis of lamellarin D 
 
The aforementioned strategy has been employed to prepare numerous open chain analogs of lamellarins 
containing the mono- and bis-aryl scaffolds 11 and 12, respectively, and their corresponding oxidized 
derivatives 13 and 14 (see Table 5) [34]. Other C4-C5-bisarylpyrrole-2-carboxylate simplified analogs 
were synthesized by Banwell et al. [35].  
 
Lam-Q dimethyl ether and Lam-O have been synthesized from C3-C4-bisaryl pyrroles obtained by 
regioselective halogenation and Suzuki-Miyaura reaction of a 2-trichloroacetylpyrrole (Figure 13) [36] . 
N
H
CCl3
O
N
H
CO2Me
I1. I2, AgTf, CHCl3
2. MeOH, KOH
N
H
CO2Me
I
Cl
I1. SOCl2, CHCl3
2. I2, AgTFA, CHCl3
N
H
CO2Me
OMe
MeO1.
Pd(OAc)2, K2CO3, acetone
2. H2, Pd/C, MeOH
MeO B
O
O
Lam-Q dimethyl ether
 
Fig. (13). Synthesis of lamellarin Q dimethyl ether 
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Activity and mechanism of action: 
Lamellarins and their derivatives are multi-drug resistance (MDR) reversal agents. As some of them are 
highly cytotoxic, they have been tested against various cancer cell lines. The results are summarized in 
Table 3. 
 
 
Table 3. Cytotoxicity of isolated lamellarins to various culture cell lines 
 
Isolated Compound Culture Cell Linea IC50 (M)b Ref 
HeLa 10.5 10-9 [39] 
CEM 5 10-9 
CEM/C2 7.2 10-7 
[37] 
DU145 10.9 10-9 c [8]  
MDA-MB-231 2.5 10-7 c 
A549 2 10-7 c 
HT29 5.1 10-6 c  
 
[34]  
XC 1.24 10-8 
Vero Cells 1.05 10-8 
Lam-D 
MDCK 2.25 10-8 
 
[39]  
Lam-F COLO205 9 10-9 [8]  
Lam-H HeLa >10-6 [39] 
HeLa 1.15 10-5 [39]  
CEM 1.95 10-6 
Lam-H hexaacetate 
CEM/C2 6.93 10-6 
 [37] 
Lam-L triacetate COLO205 0.25 10-9 [8] 
Lam-N HeLa 5 10-6 [9] 
Lam-T HeLa 2.7 10-5 d [9] 
Lam-U sulf HeLa 1.4 10-4 d [9] 
Lam-V sulf HeLa 1.3 10-4 d [9] 
Lam-W HeLa 2.8 10-4 d [9]  
Lam-α HeLa 5.1 10-6 d [49] 
Lam-α sulf HeLa 2.74 10-4 d [9] 
Lam-ζ COLO205 5.6 10-9 [8] 
Lam-χ DU145 2.99 10-6c  [8] 
Lam-χ triacetate COLO205 0.2 10-9 [8] 
HeLa 2.5 10-6 [39] 
CEM 3.03 10-6 
CEM/C2 5.55 10-6  [37] 
Lam-η 
COLO205 1.78 10-7 [8]  
Lam-dihydro η COLO205 5 10-8 [8] 
Lam-φ COLO205 5.6 10-8 [8] 
 
a: cervical cancer cells (HeLa); human leukemic lymphoid cells (CEM); human leukemia cells resistant to 
camptothecin (CEM/C2); human prostate carcinoma cells (DU145); Rous sarcoma virus transformed rat cell line (XC); 
monkey kidney epithelial cells (Vero cells); Madin-Darby canine kidney cells (MDCK); colon cancer cells 
(COLO205); human breast adenocarcinoma cancer cells (MDA-MB-231); human colon cancer cells (HT29); human 
lung cancer cells (A549); b: IC: inhibitory concentration (in most cases the values not comparable, because the assays 
were performed in different conditions); c: GI: growth inhibition; d) LD: lethal dose 
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Lam-D, Lam-K and Lam-M are among the most cytotoxic molecules in the series. The best studied 
member is Lam-D, which is highly cytotoxic to a wide range of tumor cell lines, particularly human 
prostate cancer cells [8] and leukemia cells [37]. Several molecular targets have been described for Lam-D 
and other lamellarins.  
 
Molecular structure-activity determinants 
Lamellarins with a C8-C9 double bond are generally more cytotoxic than their corresponding saturated 
analogs. This is very clear in the case of Lam-D, which is considerably more cytotoxic than its synthetic 
saturated analog, Lam-501 (Figure 14), which has no effect on topoisomerase I. As such, Bailly et al. 
postulated that the planarity of the pentacyclic structure is important for cytotoxicity [38].  
 
HO
N
O
MeO OH
MeO
HO
O
MeO
Lam-D
HO
N
O
MeO OH
MeO
HO
O
MeO
Lam-501
 
 
Fig. (14). The structures of lamellarin 501 and lamellarin D 
 
Ishibashi et al. synthesized several derivatives of Lam-D [39], then evaluated the compounds for 
cytotoxicity against a HeLa cell line to determine the SAR. Their results are summarized in Table 4. Most 
of the derivatives with hydroxyl groups at both the C-3 and C-11 positions (15a, 15c, 15f and 15g) showed 
quite high activity, with IC50 values of 10.5-70.0 nM. The low toxicity of 15b might be partly due to its low 
solubility in the assay medium. The hydroxyl substituent at C-3 appears to be a prerequisite for activity, 
since the activity of 15d (IC50, 0.85 µM), which lacks the hydroxyl group, was markedly lower than that of 
15a (IC50, 10.5 10-3 µM). The importance of the 3-hydroxyl group for bioactivity is also apparent when 
comparing the activity of 15e (IC50 2.5 µM) with those of 15k (IC50, 5.7 µM) and 15l (IC50 >100 µM). The 
hydroxyl group at C-11 might also be important for activity, since methylation of both hydroxyl groups at 
C-11 and C-4’ of 15a and 15e leads to much lower activity. In contrast, 15g, which has the 11-hydroxy 
group but lacks the 4’-hydroxyl group of 15a, still maintains high activity. The presence of a hydroxyl 
group at C-4’, and methoxy groups at C-3’ and C-2, does not appear to affect activity, since the 4’-
dehydroxy, 3’-demethoxy, and 2-demethoxy derivatives (15g, 15f, and 15c, respectively) displayed slightly 
lower activity than the parent compound. In conclusion, this study provided basic SAR on Lam-D: 
hydroxyl groups at the C-3 and C-11 positions of 15a appear to be essential for cytotoxicity.  
 
Table 4. Cytotoxic activity of lamellarin derivatives 15a-l on HeLa Cells [39] 
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3
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Compound R1 R2 R3 R4 R5 R6 IC50 (µM) 
15a OMe OH OH OMe OMe OH 10.5 10-3 
15b OH OH OH OH OH OH >100 
15c H OH OH OMe OMe OH 39.5 10-3 
15d OMe H OH OMe OMe OH 0.85 
15e OMe OH OMe OMe OMe OMe 2.5 
15f OMe OH OH OMe H OH 38.0 10-3 
15g OMe OH OH OMe OMe H 70.0 10-3 
15h H H OH OMe OMe OH 4.0 
15i H H OH OH OH OH 1.1 
15j OAc OAc OAc OAc OAc OAc 11.0 
15k H H OMe OMe OMe OMe 5.7 
15l -OCH2O- OMe OMe OMe OMe >100 
 
These results agree with those of a molecular dynamics study performed by Iwao et al. [37] to establish 
molecular interactions for the complex of Lam-D and the enzyme topoisomerase I. These researchers 
proposed that the guanidinium group of Arg364 maintains a close relationship with the lactone ring of the 
molecule. Moreover, they observed that direct hydrogen bonding interactions between the 3-OH oxygen 
and the Glu356 carboxylate oxygen, and between the 11-OH oxygen and the side chain amide nitrogen of 
Asn722, were maintained throughout the entire simulation.  
 
A library of open lactone analogs of Lam-D [34] was recently synthesized (Table 5). The 45 members of 
the library all feature a methyl 8-hydroxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate scaffold, 
which differs from Lam-D primarly in that it lacks a lactone ring. The absence of the pyranone ring affords 
flexibility to the derivatives, and more importantly, greater solubility. Two series of compounds were 
prepared: derivatives of the 1-aryl-scaffold and of the 1,2-diaryl-scaffold. Members of both series feature 
either a single or double bond between C5 and C6 (which correspond to the C8 and C9 in lamellarins). The 
compounds from each series differ in their respective numbers and positions of the OH/OMe substituents 
on the aryl rings, and in the presence of functional groups such as NO2, NMe2, OCF3 and heterocycles 
instead of aryl rings. All the compounds were tested for cytotoxicity against a panel of three human tumor 
cell lines: A-549 lung carcinoma, HT-29 colon carcinoma and MDA-MB-231 breast adenocarcinoma. The 
most active compounds are shown in Table 5. 
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Table 5. Cytotoxicity (GI50 µM) of open-lactone lamellarin analogs to various cancer cell lines [34] 
R3
N
CO2MeMeO
HO
R2
R1
R4 R3
N
CO2Me
R5
R8 R7
MeO
HO
R2 R
6
R1
R4
1
11
13
12
14
 
Cmpd. Bda R1 R2 R3 R4 R5 R6 R7 R8 A-549b HT-29c 
MDA-
MB-
231d 
Lam-D 0.20 5.1 0.25 
11a S H OMe OH H -- -- -- -- 14.2 18.0 22.3 
11b S OMe H H OMe -- -- -- -- n.a. n.a. 12.7 
12a S H OMe OH H H OMe OH H 14.3 n.a. 8.5 
12b S H OMe OMe H H OMe OMe H 11.2 n.a. 7.7 
12c S H H OMe H H H OMe H 9.2 10.3 14.4 
12d S H H NMe2 H H H NMe2 H n.a. n.a. 13.7 
12e S H NO2 H H H NO2 H H 18.0 11.3 10.1 
12f S H OMe OH H OH H OH OMe 5.0 17.1 3.1 
12g S H OMe OH H OMe H OH OMe 8.9 n.a. 7.6 
12h S OMe H H OMe OH H OH OH 13.7 8.4 10.5 
12i S H OH H H OH H OH H n.a. n.a. 19.0 
12j S H OH H H OH OMe OMe H 14.7 n.a. 15.7 
13a D H OMe OH H -- -- -- -- 10.9 23.9 11.2 
13b D OMe H H OMe -- -- -- -- 13.3 n.a. 19.9 
13c D 1-(2-thienyl) -- -- -- -- n.a. n.a. 26.3 
14a D H OMe OH H H OMe OH H 7.1 8.1 7.5 
14b D H H OMe H H H OMe H n.a. 9.7 9.9 
14c D H H OH H H H OH H 3.5 9.8 4.1 
14d D H OH H H H OH H H 6.3 18.4 7.2 
14e D H NO2 H H H NO2 H H n.a. 8.9 18.3 
14f D 1,2-bis(2-thienyl) 20.4 n.a. 19.7 
14g D H OMe OH H H H OH H 9.8 10.1. 15.0 
14h D H OMe OH H OH H OH OMe 0.45 7.9 0.71 
14i D OMe H H OMe OH H OH OH 4.7 7.1 3.2 
14j D H OH H H OH H OH H 20.8 n.a. 10.6 
 
a: Bond C5-C6 S = single and D = double; b: human lung carcinoma cells (A-549); c: human colon carcinoma cells 
(HT-29); d: human breast adenocarcinoma cells (MDA-MB-231) 
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Structurally simplified analogs of Lam-D, in which the lactone ring was removed, and, in the case of 
derivatives 11 and 13, an additional aryl group was removed, all had lower activity than Lam-D.  These 
data reveal that the complete structure is crucial for biological activity, despite being less soluble in 
biological media than simpler molecules. In a general overview, oxidized derivatives showed greater 
activity than the corresponding reduced analogs [34]. These data reveal that the complete structure is 
crucial for biological activity, despite being less soluble in biological media than simpler molecules. In a 
general overview, oxidized derivatives showed greater activity than the corresponding reduced analogs. 
This fact can probably be attributed to the greater hydrogen bonding capacity of these analogs—namely, 
with active sites, as has been described for Lam-D [37]. The donor effect of the methoxy-substituents may 
explain why 12c and 14b were quite active despite not being able to act as hydrogen bond donors. 
Compounds 14g, 14a, 14h and Lam-D have identical substituents on their scaffolds and at position 1 of 
their aryl rings. For these compounds, the greater the substitution of the aryl ring at position 2 of the 
scaffold, the lower the activity. The simplified analog 14a maintained 63% of activity of Lam-D in HT29 
cells, and 14g, which has a hydroxy group at C4” (the same position as C-3 in Lam-D) was nearly as active. 
The open lactone compound 14h may undergo lactonization in physiological conditions. Therefore, 14h 
merits further study as a pharmacodynamic improvement on Lam-D, a validated lead compound. 
 
Topoisomerases, the initial biomolecular engines of cell growth 
Topoisomerases, nuclear enzymes than can change the topology of DNA [40, 41], are amongst the most 
promising targets for inhibiting cellular proliferation. DNA topoisomerases are crucial in cellular 
replication; hence, they are especially attractive targets for cancer therapy. Interaction of a drug with a 
DNA topoisomerase can produce a stable, cytotoxic complex that inhibits post-cleavage DNA religation 
processes [42]. Indeed, this mode of action has been reported as a novel mechanism for many anticancer 
drugs [41]. 
 
Inhibition of topoisomerase I by Lam-D has been extensively studied in the past few years. Cancer cells are 
more susceptible to the DNA damage incurred, and thus are more likely to die. Hence, drugs targeted at 
topoisomerase I are selective for malignant cells. Like integrases, topoisomerases also cleave and join 
DNA, but via different pathways. The cytotoxicity of Lam-D is at least partly closely related to its 
inhibition of topoisomerase I. Interestingly, Vanhuyse et al. [43] reported that camptothecin-resistant 
P388CPT5 murine leukemia cells have a low relative index of resistance to Lam-D. Therefore, 
topoisomerase I is a privileged intracellular target for Lam-D. 
N
N
O
O
OOH
(S)-(+)-Camptothecin
 
Fig. (15). Structure of (+)-camptothecin 
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P glycoprotein, the most common protein efflux pump in cells, also highly favours the activity of Lam-D in 
detrimental of recognized substrates like camptothecin. Investigations into the mechanism of action of 
Lam-D revealed that it is not sensitive to MDR-mediated drug efflux by P glycoprotein without active 
transporters to carry it out of the cell cytoplasm. 
Although the pro-apoptotic effects of Lam-D could be understood as the final consequence of its 
stabilization of topoisomerase complexes, experiments [44] have revealed that it has other cellular targets. 
It has also been suggested that Lam-D induces apoptosis of leukemia cells by disrupting the mitochondrial 
transmembrane potential (MTP).  
Using reliable real-time flow cytometry techniques and swelling of mitochondria isolated from leukemia 
cells, Bailly et al. showed that Lam-D directly induces MPT. Furthermore, they discovered that 
mitochondria are required to mediate Lam-D–induced nuclear apoptosis in a cell-free system [44]. 
In summary, Lam-D is rich in pharmacological potential which should be exploited for the development of 
treatments against chemoresistant cancer cells.  
 
Docking of LAM-D with topoisomerase I  
Computational techniques have been used to elucidate the structural basis and the mode of interaction of 
the covalent complex formed by Lam-D, topoisomerase I and DNA [37, 38]. Staker et al. [45] published a 
2.10 Å resolution crystal structure of human topoisomerase I covalently linked to double-stranded DNA 
(Protein Data Bank entry 1k4t) and the chemotherapy drug topotecan. It was used to model the Lam-D-
mediated stabilization of topoisomerase I–DNA complex.  
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Fig. (16). Crystallographic model of topotecan–DNA–topoisomerase (Protein Data Bank entry 1k4t) 
featuring Lam-D superimposed in the active site [35] 
 
Bailly et al. removed topotecan from the original structure to obtain a template on which to model the drug-
free covalent complexes. The main difference between the two approaches [37, 38] remains in the 
exocyclic phenyl ring of Lam-D, which is rotated 180° relative to the conformation reported in a previous 
very similar proposal, such that the methoxy group at C13 is close to the 6-amino group of adenosine in the 
major groove. 
Finally, to support the latter refined [37] model of the cleavable Top1-DNA complex stabilized by Lam-D, 
a quantitative estimation of the contribution to the free energy of binding of the crucial 20-OH group was 
obtained through a set of precise, thermodynamic-integration free-energy simulations. 
The inhibition of topoisomerase functionality alone probably does not result in cell death, but when the 
Lam-D stabilized ternary complex encounters a replication fork, the single DNA strand break is converted 
into a double DNA strand break which kills the cell. 
 
Lam-D: taking control of mitochondria 
Mitochondria [46, 47] are subcellular organelles evolved from bacterial symbiosis and therefore contain 
their own genome. Cancer cells have unlimited replicative potential; are resistant to cell death stimuli; 
exhibit several mitochondrial disorders (e.g. dysfunction, and genetic instability with alterations such as 
mutations, deletions or translocations of the mitochondrial DNA [mtDNA]); and are highly glycolytic. The 
rapid and continuous growth of tumor cells is highly energy-dependent, and cancer cells often develop drug 
resistance, consequently becoming unaffected by pro-apoptotic signals. The dependency of cancer cells on 
glycolysis for ATP synthesis indicates that the mitochondrial engineering of the respiratory chain might be 
inefficient. The significance of mitochondria in mediating apoptosis has led to an interest in exploiting 
radio- and chemo-therapeutic agents to trigger cancer cell death. To date, direct and specific targeting of 
mitochondria to obtain a persistent antitumor response has not been achieved, but there have been several 
encouraging cases in which some level of activity was reached. The vast majority of conventional anti-
cancer drugs indirectly exploit mitochondria to exert cytotoxicity via multiple activation pathways that 
implicate p53 or death receptors. 
mtDNA metabolism can also be targeted by topoisomerase inhibitors. Type I and type II topoisomerases 
have been identified in mitochondria, and have been shown to be inhibited there by known topoisomerase 
inhibitors. 
Lam-D induces early disruption of the inner MPT through induction of pore opening [44]. This is 
considered as a predominant mechanism for mediating the release of pro-apoptotic molecules such as 
cytochrome c to the cytoplasm. Hence, agents that permeabilize cancer cell mitochondria may eliminate the 
resistance of these cells to apoptosis. Early studies have revealed that MPT pore opening precedes the 
proteolytic activation of caspase-3 in Lam-D mediated apoptosis. Furthermore, a greater gain in cell 
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depolarization was observed in tumor cells (P388 leukemia, A549 lung cancer and MCF-7 breast cancer) 
rather than in non-tumor ones (NIH3T3 fibroblasts and H9C2 cardiomyocytes). The direct targeting of 
mitochondria by Lam-D is highly advantageous over classical anticancer drugs. Lam-D may be effective 
for treating cancers in which signal transducing systems are interrupted (e.g. those implying mutations of 
p53). 
 
Focus on HIV integrase  
Current HIV treatments comprise reverse transcriptase inhibition, which prevents single-stranded viral 
RNA genome form being translated into double stranded DNA, and protease inhibition, which blocks the 
production of mature infectious virions. Whereas drugs that target these two viral enzymes have been in use 
for more than ten years, inhibitors of the third HIV enzyme, integrase (IN), have yet to be developed. 
Integrase is a viral protein of 32 kDa responsible for the insertion of newly reverse-transcribed double-
stranded viral DNA into the host genome [48]. An IN inhibitor could offer improvements in selectivity, 
despite the fact that the enzyme is only briefly active in the replication cycle of the virus. Integration of 
viral DNA into host cell chromosomal DNA to form a provirus is an essential step in the viral life cycle. IN 
is an ideal target for drug design because it does not have any known cellular homologs in mammals, and 
therefore, the reactions that it catalyzes are unique. Moreover, IN is required for viral replication and 
mutations in key residues. During the past 15 years many IN inhibitors have been identified, some of which 
are highly selective against IN and block viral replication. IN inhibitors fall into two major classes: 
catechol-containing hydroxylated aromatics and diketoacid-containing aromatics.  
The mechanisms by which small molecule inhibitors of recombinant HIV-1 IN act are unknown. Important 
structural motifs identified to date for HIV-integrase inhibitors are 1,2- and 1,4-diphenols, which can  be 
oxidated to the corresponding quinones [49, 50].  
Ridley et al. [50] reported that the sulfate group is critical for the anti-HIV-1 integrase activity of Lam-α 
20-sulfate, because Lam-α showed no inhibition of HIV-1 integrase at concentrations up to 1.6 µM. HIV-1 
integrase has been demonstrated to be a DNA manipulating enzyme and is a rarely exploited target. The 
low cytotoxicity of the sulfate compounds is interesting in the context of antiviral agents. Indeed, during a 
screening program aimed at identifying inhibitors of HIV-1 integrase. Reddy et al. [9] discovered that Lam-
α 20-sulfate [25] strongly inhibited both terminal cleavage of integrase and strand transfer in vitro. 
However, they reported that the disulfate analog Lam-α 13,20-disulfate is less selective than Lam-α 20-
sulfate, as they observed it to inhibit molluscum contagiosum virus (MCV) topoisomerase at roughly the 
same concentration as that used in the HIV-1 integrase assay.  
Lam-H—which has six OH groups, all ortho to each other—exhibited very potent inhibition of HIV-1 
integrase (IC50=1.3 µM), but unfortunately, was even more active in the non-selective MCV topoisomerase 
counterscreen (IC50=0.23 µM). It was very cytotoxic toward HeLa cells (LD50=5.7 µM).  
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Table 6. Inhibition of HIV-1 integrase and of MCV topoisomerase, and cytotoxicity, of several lamellarin 
sulfates [9, 50] 
 
Compound IC50 Integrase (µM) IC50 MCV (µM) LD50 Cytotoxicity (µM) 
Lam-H a 1.3 0.23 5.7 
Lam-N b 19 100 5 
Lam-T b 24 100 27 
Lam-U 20-sulfate b 25 500 145 
Lam-V 20-sulfate b 51 500 130 
Lam-W b 14 170 28 
Lam-α a > 1600 ND 5.1 
Lam-α 20-sulfate a, b 22 ≥ 170 274 
Lam-α 13,20-disulfatea 49 70 29 
Infection assays were performed using either (a) HeLa cells or (b) p4 – 2 cells.  
  
This review clearly illustrates the importance of natural products in drug discovery as well as in the 
development of new synthetic methods. Since first being isolated from natural sources, lamellarins have 
been extensively screened against numerous therapeutic targets and have inspired novel synthetic strategies 
for natural targets and related analogs. 
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Abbreviations 
A549 human lung cancer cells  
CEM human leukemic lymphoid cells  
CEM/C2 human leukemia cells resistant to camptothecin  
COLO205 colon cancer cells  
DCE dichloroethane 
DDQ 2,3-dichloro-5,6-dicyanoquinone 
DIEA diisopropylethylamine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DOPA 3,4-dihydoxyphenylalanine 
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DTBMP 2,6-di-tert-butyl-4-methylpyridine 
DU145 human prostate carcinoma cells  
GI growing inhibition 
H9C2 fetal rat heart cells 
HeLa cervical cancer cells  
HIV human immunodeficiency virus 
HT 29 human colon cancer cells  
IC Inhibitory concentration 
IN integrase 
Lam lamellarin 
LD letal dose 
MCV molluscum contagiosum virus  
MCF-7 human breast adenocarcinoma cells 
MDA-MB-231 human breast adenocarcinoma cancer cells  
MDCK Madin-Darby canine kidney cells  
MDR multidrug resistant or resistance 
MR Merrifield resin 
MTP mitochondria transmembrane potential 
NIH3T3 mouse embryonic fibroblast cells 
NBS N-bromosuccinimide 
PVPHP polymer bound pyridine hydrobromide perbromide 
SAR structure activity relationship 
SPS solid-phase synthesis 
Tf triflate 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TIPS triisopropylsilyl 
Top-1 topoisomerase 1 
Ts tosyl 
XC sarcoma virus transformed rat cell line 
WR Wang resin 
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Table 1. Structure of reduced pentacyclic lamellarins 
N
O
O
R7
R8 R
2R1
R5
R6
R4
R3
R9
89
 
 
Lamellarins R1 R2 R3 R4 R5 R6 R7 R8 R9 Ref 
Lam-A OMe OH OH OMe OMe OMe OMe OH H [1]  
Lam-C OMe OH H OMe OMe OMe OMe OH H [1]  
Lam-C sulf. OMe OSO3Na H OMe OMe OMe OMe OH H [2]  
Lam-E OMe OH H OH OMe OMe OH OMe H [3]  
Lam-F OMe OH H OH OMe OMe OMe OMe H [3]  
Lam-G OH OMe H H OH OMe OH OMe H [3]  
Lam-G sulf. OH OMe H OSO3Na OH OMe OH OMe H [2]  
Lam-I OMe OH H OMe OMe OMe OMe OMe H [4]  
Lam-J OMe OH H H OH OMe OMe OMe H [4]  
Lam-K OMe OH H OH OMe OMe OMe OH H [4]  
Lam-L OMe OH H H OH OMe OH OMe H [4]  
L sulf. OMe OSO3Na H H OH OMe OH OMe H [2]  
Lam-S OH OH H H OH OMe OH OH H [2]  
Lam-T OMe OH H OMe OMe OMe OH OMe H [5]  
Lam-T sulf. OMe OSO3Na H OMe OMe OMe OMe OH H [5]  
Lam-U OMe OH H H OMe OMe OH OMe H [2]  
Lam-U sulf. OMe OSO3Na H H OMe OMe OH OMe H [5]  
Lam-V OMe OH OH OMe OMe OMe OH OMe H [5]  
Lam-V sulf. OMe OSO3Na OH OMe OMe OMe OH OMe H [5]  
Lam-Y OMe OH H H OMe OH OH OMe H [2]  
Lam-Y sulf. OMe OSO3Na H H OMe OH OH OMe H [5]  
Lam-Z OH OMe H H OH OMe OH OH H [2]  
Lam-β OMe OH H H OH OH OH OMe H [6]  
Lam-γ OMe OH H OH OMe OMe OH OMe OMe [7]  
Lam-χ triacetate OMe OAc H H OAc OMe OMe OAc H [8]  
Dihydro- Lam- η OMe OH H H OMe OMe OMe OMe H [8]  
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Table 2. Structure of oxidized pentacyclic lamellarins 
 
N
O
O
R6
R7 R
2R1
R4
R5
R3
8
9
 
 
 
Lamellarins R1 R2 R3 R4 R5 R6 R7 Ref 
Lam-B OMe OH OMe OMe OMe OMe OH [1]  
Lam-B sulf. OMe OSO3Na OMe OMe OMe OMe OH [2]  
Lam-D OMe OH H OH OMe OMe OH [1]  
Lam-H OH OH H OH OH OH OH [3] 
Lam-M OMe OH OH OMe OMe OMe OH [4]  
Lam-N OMe OH H OH OMe OH OMe [4]  
Lam-W OMe OH OMe OMe OMe OH OMe [5]  
Lam-X OMe OH OH OMe OMe OH OMe [2]  
Lam-α OMe OH H OMe OMe OH OMe [7] 
Lam-α sulf. OMe OSO3Na H OMe OMe OH OMe [9]  
Lam-ζ OMe OH OMe OMe OMe OMe OMe [8]  
Lam- Є OMe OH OH OMe OMe OMe OMe [7]  
Lam-η OMe OH H OMe OMe OMe OMe [8]  
Lam-φ OMe OAc OMe OMe OAc OMe OAc [8]  
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Table 3. Cytotoxicity of isolated lamellarins to various culture cell lines 
 
Isolated Compound Culture Cell Linea IC50 (M)b Ref 
HeLa 10.5 10-9 [39] 
CEM 5 10-9 
CEM/C2 7.2 10-7 
[37] 
DU145 10.9 10-9 c [8]  
MDA-MB-231 2.5 10-7 c 
A549 2 10-7 c 
HT29 5.1 10-6 c  
 
[34]  
XC 1.24 10-8 
Vero Cells 1.05 10-8 
Lam-D 
MDCK 2.25 10-8 
 
[39]  
Lam-F COLO205 9 10-9 [8]  
Lam-H HeLa >10-6 [39] 
HeLa 1.15 10-5 [39]  
CEM 1.95 10-6 
Lam-H hexaacetate 
CEM/C2 6.93 10-6 
 [37] 
Lam-L triacetate COLO205 0.25 10-9 [8] 
Lam-N HeLa 5 10-6 [9] 
Lam-T HeLa 2.7 10-5 d [9] 
Lam-U sulf HeLa 1.4 10-4 d [9] 
Lam-V sulf HeLa 1.3 10-4 d [9] 
Lam-W HeLa 2.8 10-4 d [9]  
Lam-α HeLa 5.1 10-6 d [49] 
Lam-α sulf HeLa 2.74 10-4 d [9] 
Lam-ζ COLO205 5.6 10-9 [8] 
Lam-χ DU145 2.99 10-6c  [8] 
Lam-χ triacetate COLO205 0.2 10-9 [8] 
HeLa 2.5 10-6 [39] 
CEM 3.03 10-6 
CEM/C2 5.55 10-6  [37] 
Lam-η 
COLO205 1.78 10-7 [8]  
Lam-dihydro η COLO205 5 10-8 [8] 
Lam-φ COLO205 5.6 10-8 [8] 
 
a: cervical cancer cells (HeLa); human leukemic lymphoid cells (CEM); human leukemia cells resistant to 
camptothecin (CEM/C2); human prostate carcinoma cells (DU145); Rous sarcoma virus transformed rat cell line (XC); 
monkey kidney epithelial cells (Vero cells); Madin-Darby canine kidney cells (MDCK); colon cancer cells 
(COLO205); human breast adenocarcinoma cancer cells (MDA-MB-231); human colon cancer cells (HT29); human 
lung cancer cells (A549); b: IC: inhibitory concentration (in most cases the values not comparable, because the assays 
were performed in different conditions); c: GI: growth inhibition; d) LD: lethal dose. 
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Table 4. Cytotoxic activity of lamellarin derivatives 15a-l on HeLa Cells [39] 
R6
N
O
R1 R2
R4
R3
O
R5
3
11
 
Compound R1 R2 R3 R4 R5 R6 IC50 (µM) 
15a OMe OH OH OMe OMe OH 10.5 10-3 
15b OH OH OH OH OH OH >100 
15c H OH OH OMe OMe OH 39.5 10-3 
15d OMe H OH OMe OMe OH 0.85 
15e OMe OH OMe OMe OMe OMe 2.5 
15f OMe OH OH OMe H OH 38.0 10-3 
15g OMe OH OH OMe OMe H 70.0 10-3 
15h H H OH OMe OMe OH 4.0 
15i H H OH OH OH OH 1.1 
15j OAc OAc OAc OAc OAc OAc 11.0 
15k H H OMe OMe OMe OMe 5.7 
15l -OCH2O- OMe OMe OMe OMe >100 
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Table 5. Cytotoxicity (GI50 µM) of open-lactone lamellarin analogs to various cancer cell lines [34] 
R3
N
CO2MeMeO
HO
R2
R1
R4 R3
N
CO2Me
R5
R8 R7
MeO
HO
R2 R
6
R1
R4
1
11
13
12
14
 
Cmpd. Bda R1 R2 R3 R4 R5 R6 R7 R8 A-549b HT-29c 
MDA-
MB-
231d 
Lam-D 0.20 5.1 0.25 
11a S H OMe OH H -- -- -- -- 14.2 18.0 22.3 
11b S OMe H H OMe -- -- -- -- n.a. n.a. 12.7 
12a S H OMe OH H H OMe OH H 14.3 n.a. 8.5 
12b S H OMe OMe H H OMe OMe H 11.2 n.a. 7.7 
12c S H H OMe H H H OMe H 9.2 10.3 14.4 
12d S H H NMe2 H H H NMe2 H n.a. n.a. 13.7 
12e S H NO2 H H H NO2 H H 18.0 11.3 10.1 
12f S H OMe OH H OH H OH OMe 5.0 17.1 3.1 
12g S H OMe OH H OMe H OH OMe 8.9 n.a. 7.6 
12h S OMe H H OMe OH H OH OH 13.7 8.4 10.5 
12i S H OH H H OH H OH H n.a. n.a. 19.0 
12j S H OH H H OH OMe OMe H 14.7 n.a. 15.7 
13a D H OMe OH H -- -- -- -- 10.9 23.9 11.2 
13b D OMe H H OMe -- -- -- -- 13.3 n.a. 19.9 
13c D 1-(2-thienyl) -- -- -- -- n.a. n.a. 26.3 
14a D H OMe OH H H OMe OH H 7.1 8.1 7.5 
14b D H H OMe H H H OMe H n.a. 9.7 9.9 
14c D H H OH H H H OH H 3.5 9.8 4.1 
14d D H OH H H H OH H H 6.3 18.4 7.2 
14e D H NO2 H H H NO2 H H n.a. 8.9 18.3 
14f D 1,2-bis(2-thienyl) 20.4 n.a. 19.7 
14g D H OMe OH H H H OH H 9.8 10.1. 15.0 
14h D H OMe OH H OH H OH OMe 0.45 7.9 0.71 
14i D OMe H H OMe OH H OH OH 4.7 7.1 3.2 
14j D H OH H H OH H OH H 20.8 n.a. 10.6 
 
a: Bond C5-C6 S = single and D = double; b: human lung carcinoma cells (A-549); c: human colon carcinoma cells 
(HT-29); d: human breast adenocarcinoma cells (MDA-MB-231) 
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Table 6. Inhibition of HIV-1 integrase and of MCV topoisomerase, and cytotoxicity, of several lamellarin 
sulfates [9, 50] 
 
Compound IC50 Integrase (µM) IC50 MCV (µM) LD50 Cytotoxicity (µM) 
Lam-H a 1.3 0.23 5.7 
Lam-N b 19 100 5 
Lam-T b 24 100 27 
Lam-U 20-sulfate b 25 500 145 
Lam-V 20-sulfate b 51 500 130 
Lam-W b 14 170 28 
Lam-α a > 1600 ND 5.1 
Lam-α 20-sulfate a, b 22 ≥ 170 274 
Lam-α 13,20-disulfatea 49 70 29 
Infection assays were performed using either (a) HeLa cells or (b) p4 – 2 cells.  
 
 
